This compound is a dual agonist metabolic therapy that activates both GLP 1 and GIP receptors. By combining these two incretin pathways, it provides stronger effects on appetite control, insulin sensitivity, and metabolic function than traditional single pathway treatments.
It is widely studied for its impact on body weight regulation, blood sugar management, and overall metabolic health.
Four Key Benefits Commonly Discussed in Research
1. Powerful Appetite and Craving Control
Dual incretin signaling reduces hunger, slows gastric emptying, and enhances feelings of fullness.
2. Significant Body Weight Reduction
Research consistently shows marked decreases in body weight and body fat due to reduced intake and improved metabolic signaling.
3. Improved Blood Sugar Regulation
The GIP/GLP 1 combination enhances insulin sensitivity, lowers fasting glucose, and supports healthier post meal glucose responses.
4. Support for Cardiometabolic Health
Studies often report improvements in markers such as cholesterol, inflammation, and insulin resistance.
Safety Precautions & Compliance
⚠️ FOR RESEARCH USE ONLYThis compound is provided exclusively for laboratory research purposes. It is strictly prohibited for human or animal consumption, medical use, or therapeutic application.
- Reconstitution Requires careful handling and sterile diluent. Staff will not provide guidance on dosing or mixing.
- Handling Must be handled only by qualified researchers in controlled environments.
Reviews
There are no reviews yet.